Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy
- 30 March 2009
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 65 (3), 286-293
- https://doi.org/10.1002/ana.21577
Abstract
Objective Report a double‐blind, placebo‐controlled study of rituximab in patients with anti–MAG demyelinating polyneuropathy (A‐MAG‐DP). Methods Twenty‐six patients were randomized to four weekly infusions of 375mg/m2 rituximab or placebo. Sample size was calculated to detect changes of ≥1 Inflammatory Neuropathy Course and Treatment (INCAT) leg disability scores at month 8. IgM levels, anti‐MAG titers, B cells, antigen‐presenting cells, and immunoregulatory T cells were monitored every 2 months. Results Thirteen A‐MAG‐DP patients were randomized to rituximab and 13 to placebo. Randomization was balanced for age, electrophysiology, disease duration, disability scores, and baseline B cells. After 8 months, by intention to treat, 4 of 13 rituximab‐treated patients improved by ≥1 INCAT score compared with 0 of 13 patients taking placebo (p = 0.096). Excluding one rituximab‐randomized patient who had normal INCAT score at entry, and thus could not improve, the results were significant (p = 0.036). The time to 10m walk was significantly reduced in the rituximab group (p = 0.042) (intention to treat). Clinically, walking improved in 7 of 13 rituximab‐treated patients. At month 8, IgM was reduced by 34% and anti‐MAG titers by 50%. CD25+CD4+Foxp3+ regulatory cells significantly increased by month 8. The most improved patients were those with high anti‐MAG titers and most severe sensory deficits at baseline. Interpretation Rituximab is the first drug that improves some patients with A‐MAG‐DP in a controlled study. The benefit may be exerted by reducing the putative pathogenic antibodies or by inducing immunoregulatory T cells. The results warrant confirmation with a larger trial. Ann Neurol 2009;65:286–293Keywords
This publication has 31 references indexed in Scilit:
- Invited Article: Inhibition of B cell functionsNeurology, 2008
- Terminal latency index in neuropathy with antibodies against myelin‐associated glycoproteinsMuscle & Nerve, 2007
- Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of ActionAmerican Journal of Transplantation, 2006
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathiesPublished by Wiley ,2003
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- Autoimmune ataxic neuropathies (sensory ganglionopathies): Are glycolipids the responsible autoantigens?Annals of Neurology, 1996
- Do anti-ganglioside antibodies cause human peripheral neuropathies?JCI Insight, 1996
- Demyelination induced by intraneural injection of human antimyelin‐associated glycoprotein antibodiesMuscle & Nerve, 1988